Literature DB >> 24371631

Her-2 targeting in uterine papillary serous carcinoma.

Sumit Talwar1, Seth Cohen1.   

Abstract

► A case of metastatic uterine papillary serous cancer with Her-2 gene amplification. ► Was treated with a Her-2 targeted agent and achieved durable remission. ► Her-2 targeting should be considered alone or in combination with chemotherapy.

Entities:  

Keywords:  Endometrial cancer; Her-2; Papillary serous carcinoma; Targeted therapy

Year:  2012        PMID： 24371631      PMCID： PMC3860722          DOI： 10.1016/j.gynor.2012.05.003

Source DB:  PubMed          Journal:  Gynecol Oncol Case Rep        ISSN： 2211-338X


  7 in total

1.  Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.

Authors:  Alessandro D Santin; Stefania Bellone; Sue Van Stedum; Wendy Bushen; Michela Palmieri; Eric R Siegel; Luis E De Las Casas; Juan J Roman; Alexander Burnett; Sergio Pecorelli
Journal:  Cancer       Date:  2005-10-01       Impact factor: 6.860

2.  Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.

Authors:  Vincent A Miller; Vera Hirsh; Jacques Cadranel; Yuh-Min Chen; Keunchil Park; Sang-We Kim; Caicun Zhou; Wu-Chou Su; Mengzhao Wang; Yan Sun; Dae Seog Heo; Lucio Crino; Eng-Huat Tan; Tsu-Yi Chao; Mehdi Shahidi; Xiuyu Julie Cong; Robert M Lorence; James Chih-Hsin Yang
Journal:  Lancet Oncol       Date:  2012-03-26       Impact factor: 41.316

3.  HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications.

Authors:  J A Villella; S Cohen; D H Smith; H Hibshoosh; D Hershman
Journal:  Int J Gynecol Cancer       Date:  2006 Sep-Oct       Impact factor: 3.437

4.  Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.

Authors:  Gini F Fleming; Michael W Sill; Kathleen M Darcy; D Scott McMeekin; J Tate Thigpen; Lisa M Adler; Jonathan S Berek; Julia A Chapman; Paul A DiSilvestro; Ira R Horowitz; James V Fiorica
Journal:  Gynecol Oncol       Date:  2009-10-18       Impact factor: 5.482

5.  Her-2/neu overexpression and amplification in uterine papillary serous carcinoma.

Authors:  Brian M Slomovitz; Russell R Broaddus; Thomas W Burke; Nour Sneige; Pamela T Soliman; Weiguo Wu; Charlotte C Sun; Mark F Munsell; David M Gershenson; Karen H Lu
Journal:  J Clin Oncol       Date:  2004-08-01       Impact factor: 44.544

6.  An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study.

Authors:  T A Grushko; V L Filiaci; A J Mundt; K Ridderstråle; O I Olopade; G F Fleming
Journal:  Gynecol Oncol       Date:  2007-10-18       Impact factor: 5.482

7.  Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu.

Authors:  Alessandro D Santin; Stefania Bellone; Juan J Roman; Jesse K McKenney; Sergio Pecorelli
Journal:  Int J Gynaecol Obstet       Date:  2008-06-16       Impact factor: 3.561
  7 in total
  4 in total

1.  Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.

Authors:  C L Schwab; S Bellone; D P English; D M Roque; S Lopez; E Cocco; R Nicoletti; I Bortolomai; E Bonazzoli; E Ratner; D-A Silasi; M Azodi; P E Schwartz; T J Rutherford; A D Santin
Journal:  Br J Cancer       Date:  2014-09-30       Impact factor: 7.640

2.  Brain metastasis from uterine serous carcinoma: A case report and review of literature.

Authors:  Tania Sierra; Long Nguyen; Justin Mascitelli; Tamara Kalir; David Fishman
Journal:  Gynecol Oncol Rep       Date:  2015-01-15

3.  Evaluation of HER2/neu Expression in High-Grade Endometrial Carcinoma and Its Clinicopathological Correlation.

Authors:  Soheila Sarmadi; Narges Izadi-Mood; Nazanin Mansourzadeh; Dorna Motevalli
Journal:  Iran J Pathol       Date:  2019-09-22

4.  Rare brain metastasis with unusual characteristics in a late recurrence of stage IIIA uterine papillary serous carcinoma.

Authors:  Charles Nicolas Crain; Remy Ngwanyam; Gregory Punch
Journal:  BJR Case Rep       Date:  2021-03-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.